Calling All Cowboys: Leading Medical Device Provider Taps Professional Bull Riders to Educate Millions of Fans.

ATLANTA -- Theragenics Corporation(R) Launches National Prostate Cancer Treatment Awareness Campaign To Reach Families In The Heartland

Theragenics Corporation(R) (NYSE: TGX) will target more than 100 million men and their families in 2005 with a simple message: know your options for prostate cancer treatment. The Company has tapped two champion bull riding professionals to reach people across the country. Owen Washburn and Lee Akin will spread the word through events, appearances, advertising and a blue ribbon campaign aimed at educating fans of one of the fastest growing spectator sports in America.

The campaign will officially begin at the first Professional Bull Riders (PBR) Built Ford Tough Series event of 2005 in Worcester, Mass. on Jan. 7.

"Many men across the nation, especially in rural areas, do not have access to resources or are unaware of proven treatment options beyond surgery," said M. Christine Jacobs, Chairman, CEO and President of Theragenics(TM). "With more than 100 million viewers annually and over one million live event attendees, professional bull riding provides a unique platform to reach a large segment of the American public. We are seizing this opportunity to reach an audience that needs to hear our message and become empowered to take control of their healthcare."

Theragenics(TM), a leading provider of brachytherapy ("seeding") devices for prostate cancer treatment, including TheraSeed(R), is the first company in the healthcare industry to sponsor professional bull riders. Response to a pilot ad campaign and appearances by TheraSeed(R) spokesman Owen Washburn in 2004 exceeded the Company's expectations in support of its patient education and marketing efforts.

"The riders on the PBR tour are heroes to our loyal fans," said Randy Bernard, CEO of the PBR. "Owen and Lee are the first PBR athletes to deliver an important message about men's health. I believe this campaign can make a genuine difference in the lives of many of our fans and their loved ones."

Professional Bull Riders Speak Out

Washburn and Akin will provide information regarding prostate cancer treatment in cities throughout the U.S. in conjunction with the PBR's Built Ford Tough Series tour. Theragenics(TM) also will launch an advertising campaign in key cities to complement this grassroots effort.

Owen Washburn joined the professional bull riding circuit in 1993 and quickly established his reputation for consistency, reaching the ultimate goal of professional bull riders when he captured the 1996 PBR World Championship title.

"It's important for men to know about their options," Washburn said. "Men like me can't afford not to work for weeks or months at a time. I want to let them know about proven treatment options, like TheraSeed(R), that will get them back to their daily routine as soon as possible."

TheraSeed(R) provides cure rates comparable to surgery, yet may offer men a better chance for quality of life. The minimally invasive outpatient procedure offers faster healing times than surgery and has a lower risk of complications, such as incontinence and impotence.

Lee Akin, the top-ranked African-American bull rider on the PBR circuit, has been a professional bull rider for more than seven years. As a multiple qualifier in the PBR World Finals, he has won nearly 20 championship titles throughout his career including three PBR titles in 2003 and 2004.

"Being part of this awareness campaign is especially important to me," Akin said. "African-American men are at a higher risk of developing prostate cancer and it often strikes at an earlier age. I hope I can make a difference in someone's quality of life through my work with TheraSeed(R)."

Blue Ribbon Campaign to Raise Awareness and Support Charity

As members of "Team TheraSeed(R)," the bull riders will wear shirts and protective vests featuring a specially designed blue ribbon and the Company logo during each of their rides throughout the 2005 PBR season. Blue ribbons - designating prostate cancer treatment awareness will be handed out to fans at Built Ford Tough Series events in 2005. In addition, Theragenics(TM) will donate one dollar for every blue ribbon distributed to the first 150,000 spectators (a commitment of $150,000) to the Resistol Relief Fund, a non-profit fund established by the PBR to provide medical and financial aid to athletes who are injured in bull riding competition.

Theragenics(TM) is a prominent advocate of the need for men to understand all clinically proven options, when making their treatment decisions. The Company played a lead role in securing Congressional adoption of both Senate and House resolutions in 2004, encouraging doctors to inform patients of all proven treatment options, including brachytherapy.

"Prostate cancer affected about 230,000 men and caused an estimated 29,900 deaths in 2004," said Jacobs. "We hope to reach men and their loved ones whose lives will be impacted by this disease. Raising awareness about treatment options is crucial to fighting prostate cancer."

About Theragenics(TM)

Theragenics Corporation(R) is committed to being a leading provider of brachytherapy treatment devices for prostate cancer and other degenerative disease states. The Company is the manufacturer and marketer of the palladium-103 device TheraSeed(R) and I-Seed, an iodine-125 based device. Both devices are used in the treatment of localized prostate cancer in one-time, minimally invasive procedures. Theragenics(TM) is the world's largest producer of palladium-103 and is involved in research and development utilizing palladium-103 and other isotopes for the treatment of a wide variety of diseases, including vascular disease and macular degeneration. For additional information on the Company, call Theragenics'(TM) Investor Relations Department at [phone]. The Company's common stock is traded on the New York Stock Exchange under the symbol TGX. Additional information can be found on the Company website: www.theragenics.com and www.theraseed.com.

This release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding the potential for this campaign to reach a large segment of the American public, as well as the Company's ability to reach men and their families regarding this healthcare issue through the campaign. Actual results may differ materially as a result of a variety of factors, including, among other things, the contractual and working relationship between Theragenics(TM) and the two champion bull riding professionals, continued acceptance of brachytherapy as a treatment option for prostate cancer, the potential for new or improved treatments for prostate cancer, other positive or negative developments regarding treatments for prostate cancer going forward, competition from other prostate cancer treatments and/or other sources of brachytherapy treatment, and other factors set forth from time to time in the Company's Securities and Exchange Commission filings.

All forward looking statements and cautionary statements included in this document are made as of the date hereby based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward looking statement or cautionary statement.